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Background: An increasing number of metastatic HER2 positive cancers are diagnosed as de 
novo stage IV disease. We hypothesize that a subset of these patients, who achieve complete 
clinical response or no evidence of disease (NED) status after multi-agent HER2-targeted 
treatments may have long progression free (PFS) and overall survival (OS). 
 
Methods: 483 patients with de novo stage IV HER2 positive breast cancer diagnosed between 
1998-2015 were identified through the medical records at Yale and MD Anderson Cancer Centers. 
Treatment, clinical variables and survival were extracted and compared between those who 
achieved NED status and those who did not.  
 
Results: All patients received trastuzumab and 94 (20%) also received pertuzumab as first line 
therapy. The median OS was 5.5 years (95% Cl:4.8-6.2). Sixty-three patients (13.0%) achieved 
NED, their PFS and OS were 100% and 98% (95% CI:94.6%-100%) at 5 years and remined the 
same at 10 years. For patients with non-NED (n=420), the PFS and OS rates were 12% (95% 
CI:4.5%-30.4%) and 45% (95% CI:38.4%-52.0%) at 5 years, and 0%, and 4% (95% CI:1.3%-
13.2%) at 10 years. There was no difference in age, grade, race, year of diagnosis, ER status, 
treatment distribution, or radiation between the NED and non-NED groups. NED patients more 
frequently had solitary metastasis (79% vs 51%, p=0.005) and surgery to resect cancer (59% vs. 
22%, p≤0.001). In multivariate analysis, NED status (Hazard ratio (HR):0.014, P=0.0002) and 
hormone receptor positive status (HR:0.72; P=0.04) were associated with prolonged OS. 
 
Conclusion: Achieving NED status may be an important therapeutic goal for de novo, stage IV, 
HER-2 positive MBC. 
 
*These results were presented at the 2017 Annual Meeting of the American Society of Clinical 
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Metastatic breast cancers (MBC) can be either de novo, stage IV disease or asynchronous 
metastatic recurrence of stage I-III cancers. An important difference between these two types of 
metastatic disease is the extent of prior therapies. De novo, stage IV disease implies the presence 
of distant metastasis at the time of initial diagnosis and no prior therapy for the cancer. Metastatic 
recurrence of stage I-III breast cancer typically implies recurrence despite systemic adjuvant 
therapy. Both types of metastatic breast cancers are considered incurable and treated with palliative 
intent usually with sequential single agent or doublet therapies (1).  
 In the past 10 years, the inclusion of Human Epidermal Growth Factor Receptor 2 (HER-
2) targeted agents into the adjuvant therapy of stage I-III, HER-2 positive breast cancers have 
significantly reduced distant metastatic recurrences and improved survival (2,3,4). This has 
resulted in overall fewer HER2 positive MBC and in a relative increase in the proportion of de 
novo, stage IV disease among patients with HER-2 positive metastatic disease. Historically, de 
novo, stage IV breast cancer accounted for 6-20% of metastatic breast cancers across subtypes but 
recent studies reported that over 50% of metastatic HER-2 breast cancers today represent de novo, 
stage IV disease (5,6,7,8,9). This shift in the proportion of de novo stage IV disease raise an 
important clinical question. Should de novo stage IV, HER2 positive MBC treated differently from 
recurrent HER2 positive MBC? 
 Several studies examined whether clinical outcomes differ between de novo and recurrent 
MBC. A study that examined the prognostic impact of metastasis-free interval (MFI; i.e. the time 
between initial diagnosis and distant recurrence) on survival included 154 patients with de novo 
MBC and showed that these patients had a prolonged survival compared with patients who had a 
recurrence within 24 months. However, there was no difference in survival compared to patients 
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who recurred >24 months after diagnosis (10). Results were not presented separately for HER-2 
positive patients. Another study, focused on the outcome of HER-2 positive MBC and showed that 
patients with de novo disease (n=113) receive more aggressive first-line treatments and 
experienced longer survival compared to those with recurrent disease (n=303). In the de novo 
cohort, 54 patients who underwent surgery of the primary tumor had significantly longer 
progression free survival (PFS) (hazard ratio [HR]=0.44; 95% CI:0.26-0.72) and overall survival 
(OS) (HR=0.49; 95% CI:0.26-0.93) than those who did not have surgery (11). Several other studies 
that examined clinical features that are associated with long-term survival of HER2 positive MBC 
treated with HER2 targeted therapies identified hormone receptor positivity, oligometastatic 
disease, surgical resection of metastases and/or primary tumor and no prior exposure to HER2 
targeted therapies (in the adjuvant setting) as predictors of long-term survival (7,8,9,12-15). 
The treatment of metastatic HER-2 positive breast cancer has improved substantially over 
the past 10 years due to the introduction of four distinct HER-2 targeted drugs (trastuzumab, 
lapatinib, pertuzumab and TDM1)(16,17,18,19). Both randomized clinical trials and population 
based registries demonstrated substantial improvement in median survival of HER2 positive MBC 
in the past 15 years (8,9,12-14). As a result, many oncologists can recall anecdotal cases when 
metastatic, HER-2 positive breast cancer patients treated with HER-2 targeted drugs achieved 
complete clinical response and had no evidence of disease (NED) for a long time. This raises the 
possibility  that some patients with stage IV, HER-2 positive cancer who receive combined 
modality HER2-targeted therapies may be cured from their MBC. The patient population where 
this is the most plausible is newly diagnosed, oligo-metastatic, stage IV disease with no prior HER-




We hypothesize that a subset of patients with de novo stage IV HER-2 positive cancers can 
achieve long progression free survival (PFS) after initial combined modality HER-2 targeted 
therapies. 
Objectives 
The primary objective of this study was to assess how often patients with de novo, stage IV 
HER-2 positive MBC achieve NED with modern HER-2 targeted therapy and what their long-
term progression free and overall survival is. The secondary objective was to compare the 






In order to conduct this research, a chart review protocol was designed titled “A retrospective 
assessment of long-term survival in de novo metastatic HER-2+ breast cancer treated with HER-2 
targeted therapy” (PI: Yao Wong, Yale Human Investigations Committee (HIC)# 1607018058). 
The protocol was approved by the HIC on August 19, 2016. The Smilow Cancer Hospital, Tumor 
Registry Database and the Connecticut State Tumor Registry was queried for the names and 
medical record numbers of all HER-2 positive breast cancers diagnosed between September 30, 
1998 to December 31, 2015 to identify patients who presented with de novo, stage IV metastatic 
disease and received trastuzumab containing therapy. In order to maximize the sample size, we 
have initiated a collaboration with MD Anderson Center (MDACC); Dr Rashmi Murthy served as 
the MDACC principal investigator for the study. We have provided MDACC with the chart review 
8 
 
protocol and anonymized data without patient identifiers were transferred from MDACC to Yale 
for final joint data analysis and publication. 
Variables of Interest 
 The following information were extracted from the medical records and stored in an XL 
data: 
 Patient demographics: name, date of birth, race 
 Tumor characteristics: date of diagnosis of metastatic breast cancer, date of diagnosis 
primary breast cancer if applicable (to distinguish recurrent MBC from de novo stage IV disease 
and report on frequency of stage IV disease), estrogen and progesterone receptor status, HER-2 
status, the number of involved sites with cancer at diagnosis of metastatic cancer (1, 2-5, >5) and 
the organ site location (categorized as bone, visceral, brain or soft tissue).  
 Treatment history: If metastatic recurrence occurred after diagnosis of stage I-III cancer, 
the neoadjuvant or adjuvant chemotherapy (yes vs no, and type of regimen), adjuvant endocrine 
therapy (yes vs no, and name of agent), first line treatment agents. 
 
 
The electronic and paper record of each patient was manually reviewed by local study investigators 
and each site completed an identical data acquisition form..  We also extracted from the charts best 
response to therapy that was classified either as NED if all imaging evidence of active cancer 
resolved on imaging or non-NED. Residual sclerotic bone lesions on a computerized tomograph 
image that has turned metabolically inactive on a PET-CT or resolved on a bone scan were 
included in the NED category. Survival status was categorized as alive versus deceased and alive 





Overall survival was measured from the date of diagnosis of de novo stage IV MBC until the date 
of death or last follow-up. The PFS was calculated from the start of first-line therapy to the 
discontinuation of therapy. Survival curves were plotted using the Kaplan-Meier method and 
factors associated with overall survival and NED status were assessed using multivariate Cox and 




We identified 483 de novo, stage IV, HER2-positive MBC patients who received first line 
treatment with trastuzumab-based therapy in the two institutions combined. All patients received 
trastuzumab and 94 patients (20%) also received pertuzumab as first line therapy. The median 
follow-up for the entire cohort was 2.8 years and OS rates were 54% (n = 483; 95% CI: 48%-
60.4%) and 18% (95% Cl: 11.4%-28.3%) at 5 and 10 years, respectively. Sixty-three patients 
(13%) achieved NED status.  
 Those who achieved NED had a median age of 49 years, the majority was white (73%), 
with grade 3 (73%), ER positive (70%) tumors and 79% had single site metastasis. Fifty nine 
percent of patients with NED underwent surgery of the primary lesion and 57% had radiation 
therapy. There were no significant differences in age, grade, race, ER status or radiation treatment 
use between the NED and non-NED cohorts. However, patients in the NED cohort more frequently 
had single organ site metastasis (79% vs 51%, p = 0.005) and more often had surgery for the 
primary tumor or a metastatic lesion (59% vs. 22%, p=0.000001). Patient characteristics of the two 
cohorts are shown on Table 1. Supplementary Table 1 includes tumor characteristics and systemic 
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treatment for each of the patients who achieved NED. In multivariate analysis, having a single 
metastatic site, having surgery and oligometastatic bone and CNS involvement were associated 
with NED status (Table 2).  
Table 1. Patient and Tumor Characteristics 












































































































For the NED cohort, the median survival was not achieved at a median follow-up of 5.5 years. 
The OS rates were 98% (95% CI:94.6%-100%) at 5 and 10 years. The PFS was 100% at 5 and 
10 years indicating no progression for any of the patients who achieved NED (Figure 1 A). 
Figure 2 shows the follow-up duration and disease status of each NED patient at last follow-up.  
For patients who did not achieve NED status, the median OS was 4.7 years (95% Cl: 4.2-5.3) at 
median follow-up of 2.5 years. The OS rates were 45% (95% CI:38.4%-52.0%) and 4% (95% 
CI:1.3%-13.2%) at 5 and 10 years, respectively. The PFS rates were 12% (95% CI: 4.5%-30.4%) 
and 0% at 5 and 10 years, respectively (Figure 1 B). 
 









Table 2. Stage IV Patients - No Evidence of Disease 
PATIENT AGE STAGE ER/PR METASTATIC 
SITES 
TX 
1 32 T4dN3M1 +/+ Bone THP 
2 64 T2N0M1 +/- Bone TCH 
3 62 T1cN3aM1 +/- Visceral TCH 
4 56 T4bN3bM1 +/+ Bone TCH 
5 48 T2N0M1 +/- Visceral TCH 
6 54 T4dN3M1 -/- Bone, soft 
tissues 
TCH 
7 52 T1cN3cM1 -/- Soft tissues TH 
8 57 T4dN1M1 +/- Visceral TH 
9 65 T2N0M1 +/- Bone Herceptin, 
arimidex 
10 53 T3N2M1 -/- Visceral TCH 
11 65 T2N1M1 -/+ Visceral, bone Herceptin, 
Navelbine 
12 60 T2N3cM1 +/+ Visceral, bone TH 
13 39 T1bN0M1 +/+ Visceral TH 
14 39 T4bN3cM1 -/- Visceral, soft 
tissue 
TH, lapatinib 
15 38 T2N2M1 -/- Visceral TCH 
16 48 T4dN3cM1 -/- Soft tissues TCH 
17 68 T4dN3M1 +/- Bone TH 
18 60 T3N1M1 -/- Visceral, bone TH 
19 43 T2N1M1 -/- Visceral TH 
20 38 T4dN3aM1 -/- Bone Herceptin, 
abraxane 
21 48 T4dN3bM1 +/+ Bone TH lapatinib,  
22 53 T3N0M1 -/- Visceral TCH 
23 54 T4bN1M1 -/- Visceral TH 
24 48 T4bN3cM1 -/- Soft tissues TH 
25 52 T4dN2M1 -/- Bone TCH 
26 31 T2N3aM1 -/- Visceral TH 
27 64 T4bN1M1 -/- Bone TCH 
28 52 T4dN3cM1 -/- Visceral TCH 
29 47     T   
N1M1 
+/- Bone TCH 
30 64 T4dN3bM1 +/- Soft Tissue TH, lapatinib 
31 48 T3N1M1 +/+ Bone, soft 
tissues 
TCH 
32 32 T2N3cM1 +/+ Bone THP 
33 62 T3N1M1 +/+ Visceral THP 
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34 44 T4dN3cM1 +/+ Visceral, soft 
tissues 
TCH 
35 53 T4dN1M1 +/+ Bone TH 
36 44 T2N1M1 +/+ Bone TCH 
37 49 T3N0M1 +/+ Bone TCH 
38 49 T4dN1M1 -/- Soft tissues TH 
39 30 T2N1M1 +/+ Bone, soft 
tissues 
TH 
40 49 T2N2M1 -/- Visceral, soft 
tissues 
AC-TH 
41 59 T2N1M1 +/+ Bone THP 
42 47 T4dN1M1 +/- Visceral TCH 
43 51 T2N3aM1 +/- Bone TCH 
44 29 T2N3cM1 -/- Bone, soft 
tissues, visceral 
TH 
45 65 T4bN1M1 +/- Visceral THP 
46 29 T2N3cM1 -/- Soft tissues TCH 
47 67 T2N1M1 +/- Visceral, soft 
tissues 
TH, lapatinib 
48 46 T3N1M1 +/+ Soft tissues THP 
49 39 T1cN2bM1 +/+ Visceral TCH 
50 57 T2N1M1 +/- Visceral, soft 
tissue 
THP 
51 70 T3N1M1 -/- Visceral, soft 
tissues 
THP 
52 32 T4dN1M1 +/- Visceral tissues THP 
53 38 T4bN1M1 +/+ Bone THP 
54 59 T1cN1M1 +/+ Bone TH 
55 48 T2N1M1 +/+ Bone THP 
56 35 T4dN3cM1 -/- Soft tissues TH 
57 68 T2N3aM1 -/- Bone  TCH 
58 57 T3N0M1 -/- Visceral THP 
59 29 T4bN3cM1 +/- Bone THP 
60 51 T3N0M1 -/- Bone, soft 
tissues 
THP 
61 33 T2N1M1 +/+ Bone, visceral THP 
62 49 T1cN1M1 -/- Visceral THP 
63 61 T2N3cM1 -/- Soft tissues THP 
THP (docetaxel, trastuzumab, pertuzumab), TCH (docetaxel, carboplatin, trastuzumab), TH (docetaxel, 
trastuzumab), AC-TH (doxorubicin, cyclophosphamide, docetaxel, trastuzumab), FEC (5-fluorouracil, 




 In Cox multivariate analysis only achieving NED status (Hazard ratio (HR):0.014, 
P=0.0002) and hormone receptor positive status (HR:0.72; P=0.04) were associated significantly 
with prolonged OS (Table 3). For PFS, the Cox model did not converge due to lack of events in 
the NED group.  
Table 3. Factors associated with Overall Survival & NED status in multivariate analysis  
Overall Survival HR 95% CL P-value 
NED vs non-NED status 0.014 0.002, 0.01 2.10E-05 
Age 1.01 0.75, 1.35 0.97 
Grade (1 or 2 vs 3) 1.13 0.81, 1.58 0.48 
Hormone Receptor Status 0.72 0.53, 0.99 0.04 
Herceptin Only vs Herceptin + 
Perjeta 
0.96 0.54, 1.72 0.9 
Surgery (Y or N) 0.72 0.51, 1.01 0.06 
Radiation (Y or N) 1.17 0.86, 1.61 0.32 
No. of metastatic sites (1 vs. > or =3) 0.70 0.36, 1.37 0.30 
Visceral Involvement (Y or N)  1.34 0.90, 1.98 0.15 
Bone Involvement(Y or N) 1.43 0.94, 2.17 0.09 
CNS Involvement (Y or N) 1.43 0.79, 2.58 0.23 
 
No Evidence of Disease status Odds Ratio 95% Confidence Interval P value 
Age (> 50 vs <= 50) 0.953 0.529 to 1.711 0.871 
Grade (3 vs 1 or 2) 0.989 0.535 to 1.881 0.973 
Hormone Receptor Status (ER+ vs ER-) 0.854 0.471 to 1.556 0.603 
Number of metastatic sites (2 vs 1) 0.207 0.075 to 0.520 0.001 
Number of metastatic sites (3+ vs 1) 0.028 0.001 to 0.201 0.002 
Visceral Involvement (Yes or No) 1.809 0.873 to 3.854 0.116 
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Bone Involvement (Yes or No) 2.376 1.129 to 5.169 0.025 
CNS Involvement (Yes or No) 4.586 1.111 to 16.41 0.023 
Trastuzumab only versus trastuzumab + 
pertuzumab 
1.655 0.841 to 3.160 0.134 
Surgery (Yes or No) 4.422 2.398 to 8.343 <0.001 
Radiation (Yes or No) 0.892 0.481 to 1.556 0.716 
 
Factors significantly associated with achieving NED status were fewer number of metastatic 
sites, and having surgery of the primary lesion.  
 
Discussion 
Several single institution and registry based studies examined long-term survival of MBC and each 
of these describe a small fraction of patients who experience prolonged survival (9,13,21,22). Due 
to increasing efficacy of therapies, median survival of patients with MBC has increased in the past 
decades and a growing minority of patients experience complete clinical response with systemic 
therapies or achieve an NED status with multi-agent therapy, particularly among HER-2 positive 
patients (5,6,23). However, the primary goal of treatment remains palliative (1). Several editorials 
in the past few years hypothesized that cure may be accomplished in MBC (20,24,25). To examine 
this hypothesis, we assumed that the patients who are most likely to be cured from MBC are those 
with previously untreated, HER-2 positive cancers because of the highly effective systemic 
therapies that are available for this population.  
 In this paper, we examined long-term survival of de novo, stage IV, HER-2 positive breast 
cancers who did, or did not, achieve NED status with therapy. We found that 13% of patients 
achieved NED with trastuzumab-based therapy. This is similar to findings by Bishop et al who 
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assessed 570 HER-2 positive MBC patients and reported that 16% achieved NED with initial 
therapy (26). In contrast to our study they looked at all metastatic cases, not just the de novo subset. 
In our study, all NED patients were without disease progression at 5 years and their OS was 98% 
at 10 years. In contrast, for patients who did not achieve NED, the 10-year OS was only 4%. 
Patients who achieved NED had unique disease characteristics, they typically had single 
metastasis, often in the bone or CNS, and more frequently underwent surgery to resect the primary 
tumor or solitary metastasis. These observations are also consistent with earlier reports that 
identified oligometastatic disease, HER-2 positive status and de novo stage IV presentation as 
predictors of long-term survival without evidence of disease in MBC.  
 We suggest that the bulk of the evidence from retrospective studies indicates that achieving 
NED status in de novo, stage IV, oligometastatic, HER-2 positive breast cancer may be an 
important therapeutic goal. Dual HER-2 targeted therapies combined with chemotherapy result in 
high rates (60%-80%) of pathologic complete response rates in early stage disease (27,28) and 
aggressive multi-agent therapy has reduced distant metastatic recurrence rates and improved 
survival in locally advanced HER-2 positive breast cancers. Results from retrospective studies 
raise the possibility that a similar approach might save the life of some woman with 
oligometastatic, HER-2 positive disease. Applying the neoadjuvant treatment strategy to 
oligometastatic disease, would imply starting treatment with systemic HER-2 targeted therapy that 
has the highest probably to induce a complete response, treating until best response, resecting or 
radiating residual disease, if any, and continuing maintenance therapy with a HER-2 targeted agent 
and endocrine therapy if appropriate. Since most patients with metastatic disease eventually 
receive many, if not all, available therapies, including palliative radiation, intensifying treatment 
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early in the course of the disease in the hope of durable disease control, may not be unreasonable 
for a select group of patients. 
 Our study, and all previous retrospective studies, have important limitations. Treatment 
decisions for individual patients represented in institutional and national data bases are made in 
the context routine care and are influenced by patient preference, comorbid conditions, physician 
judgement and evolving practice standards over time. This leads to highly variable therapies for 
individual patients. Patient selection has clearly influenced our observations that is reflected by 
the significantly different baseline patient characteristics of the two response cohorts (NED versus 
non-NED). Therefore, we cannot conclude with certainty that the treatment leading to NED status 
has caused the excellent long-term survival. We also acknowledge that our follow-up is short and 
most NED patients have not been followed until 10 years, and late recurrences will occur in our 
cohort. Nevertheless, we would like to draw attention to the good outcome of a select group of 
patients who present with previously untreated, HER2 positive metastatic breast cancer and 
achieve no evidence of disease status with systemic therapy alone or with combined modality 
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